Melissa Rodríguez

851 total citations
23 papers, 688 citations indexed

About

Melissa Rodríguez is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Melissa Rodríguez has authored 23 papers receiving a total of 688 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 8 papers in Hematology and 5 papers in Oncology. Recurrent topics in Melissa Rodríguez's work include Multiple Myeloma Research and Treatments (7 papers), Protein Degradation and Inhibitors (7 papers) and Neuroendocrine Tumor Research Advances (3 papers). Melissa Rodríguez is often cited by papers focused on Multiple Myeloma Research and Treatments (7 papers), Protein Degradation and Inhibitors (7 papers) and Neuroendocrine Tumor Research Advances (3 papers). Melissa Rodríguez collaborates with scholars based in United States and China. Melissa Rodríguez's co-authors include Mingyao Liu, Ying Wang, Sung‐Gook Cho, Tingfang Yi, Gautam Sethi, Xiufeng Pang, Bharat B. Aggarwal, Zhengfang Yi, Kunrong Tan and Dali Li and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Melissa Rodríguez

20 papers receiving 681 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Melissa Rodríguez United States 10 382 208 156 143 118 23 688
Nermin Kahraman United States 16 686 1.8× 50 0.2× 41 0.3× 151 1.1× 10 0.1× 32 913
Chun‐Wen Su Taiwan 13 316 0.8× 28 0.1× 21 0.1× 101 0.7× 15 0.1× 24 486
Hong Xin United States 12 224 0.6× 21 0.1× 10 0.1× 105 0.7× 30 0.3× 17 496
Ming Ni United States 10 193 0.5× 52 0.3× 5 0.0× 240 1.7× 23 0.2× 19 438
Hyereen Kang South Korea 11 230 0.6× 67 0.3× 17 0.1× 63 0.4× 9 0.1× 18 399
Manman Deng China 15 342 0.9× 25 0.1× 12 0.1× 141 1.0× 170 1.4× 42 556
Peifen Cai China 10 345 0.9× 88 0.4× 5 0.0× 144 1.0× 18 0.2× 11 566
Shangke Huang China 13 421 1.1× 43 0.2× 23 0.1× 274 1.9× 4 0.0× 28 743
Zhimin Fan China 15 319 0.8× 16 0.1× 9 0.1× 140 1.0× 57 0.5× 32 566
Sasikumar J. Soumya India 5 246 0.6× 19 0.1× 18 0.1× 54 0.4× 13 0.1× 8 440

Countries citing papers authored by Melissa Rodríguez

Since Specialization
Citations

This map shows the geographic impact of Melissa Rodríguez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melissa Rodríguez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melissa Rodríguez more than expected).

Fields of papers citing papers by Melissa Rodríguez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melissa Rodríguez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melissa Rodríguez. The network helps show where Melissa Rodríguez may publish in the future.

Co-authorship network of co-authors of Melissa Rodríguez

This figure shows the co-authorship network connecting the top 25 collaborators of Melissa Rodríguez. A scholar is included among the top collaborators of Melissa Rodríguez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melissa Rodríguez. Melissa Rodríguez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Meisel, Jane, Tamar Sapir, Ilana Graetz, et al.. (2025). Improving adherence to CDK4/6 inhibitors in breast cancer through remote therapeutic monitoring with real-time adherence tracking and actionable alerts.. Journal of Clinical Oncology. 43(16_suppl).
2.
3.
Rennie, Christopher, et al.. (2024). Complications Following Osseointegrated Transfemoral and Transtibial Implants: A Systematic Review. Cureus. 16(3). e57045–e57045. 4 indexed citations
4.
Li, Man, et al.. (2024). Inhibitory modulation of action potentials in crayfish motor axons by fluoxetine. Synapse. 78(4). e22304–e22304. 1 indexed citations
5.
Rodríguez, Melissa & Elyse Watkins. (2022). Labor and Delivery. Physician Assistant Clinics. 7(3). 559–577.
6.
Haley, Barbara, Kiran Batra, Sunati Sahoo, et al.. (2021). A Phase I/Ib Trial of PD 0332991 (Palbociclib) and T-DM1 in HER2-Positive Advanced Breast Cancer After Trastuzumab and Taxane Therapy. Clinical Breast Cancer. 21(5). 417–424. 16 indexed citations
7.
Rodríguez, Melissa, Jeffrey A. Frost, & Agnes Schönbrunn. (2018). Real-Time Signaling Assays Demonstrate Somatostatin Agonist Bias for Ion Channel Regulation in Somatotroph Tumor Cells. Journal of the Endocrine Society. 2(7). 779–793. 1 indexed citations
8.
Ghosh, Sukhen C., Melissa Rodríguez, Susanne Kossatz, et al.. (2017). Synthesis of a Fluorescently Labeled 68Ga-DOTA-TOC Analog for Somatostatin Receptor Targeting. ACS Medicinal Chemistry Letters. 8(7). 720–725. 28 indexed citations
9.
Luo, Weijia, Peng Tan, Melissa Rodríguez, et al.. (2017). Leucine-rich repeat–containing G protein–coupled receptor 4 (Lgr4) is necessary for prostate cancer metastasis via epithelial–mesenchymal transition. Journal of Biological Chemistry. 292(37). 15525–15537. 26 indexed citations
10.
Ghosh, Sukhen C., Melissa Rodríguez, Kendra S. Carmon, et al.. (2017). A Modular Dual-Labeling Scaffold That Retains Agonistic Properties for Somatostatin Receptor Targeting. Journal of Nuclear Medicine. 58(11). 1858–1864. 9 indexed citations
11.
Rodríguez, Melissa, et al.. (2016). The Essentials of Obstacle Race Training. Human Kinetics eBooks. 2 indexed citations
12.
Fiskus, Warren, Sunil Sharma, Jun Qi, et al.. (2014). Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells. Molecular Cancer Therapeutics. 13(5). 1142–1154. 155 indexed citations
13.
Mark, Tomer M., I. Alex Bowman, Adriana Rossi, et al.. (2014). Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. Leukemia & lymphoma. 55(12). 2842–2849. 9 indexed citations
14.
Rodríguez, Melissa, Warren Fiskus, Sunil Sharma, et al.. (2014). Abstract 1721: BRD4 antagonist-based therapy exerts lethal activity against FLT3 mutation expressing AML cells resistant to FLT3 tyrosine kinase inhibitors. Cancer Research. 74(19_Supplement). 1721–1721. 1 indexed citations
15.
Devaraj, Santhana G.T., Warren Fiskus, Sunil Sharma, et al.. (2014). Abstract 3686: HEXIM1 induction exerts a mechanistic role and is a biomarker of lethal activity of BRD4 antagonist against human AML cells. Cancer Research. 74(19_Supplement). 3686–3686. 1 indexed citations
16.
Luo, Weijia, Melissa Rodríguez, Joseph M. Valdez, et al.. (2013). Lgr4 is a key regulator of prostate development and prostate stem cell differentiation. Stem Cells. 31(11). 2492–2505. 58 indexed citations
17.
Fiskus, Warren, Sunil Sharma, Jun Qi, et al.. (2013). BRD4 Antagonist and Histone Deacetylase Inhibitor: A Novel Synergistic Combination Against Human Acute Myeloid Leukemia (AML) Cells. Blood. 122(21). 485–485. 1 indexed citations
18.
Rodríguez, Melissa, Warren Fiskus, Sunil Sharma, et al.. (2013). Combined Therapy With BRD4 Antagonist and FLT3 Inhibitor Exerts Synergistic Activity Against Cultured and Primary AML Blast Progenitors Expressing FLT-ITD. Blood. 122(21). 3821–3821. 1 indexed citations
19.
Cho, Sung‐Gook, Ying Wang, Melissa Rodríguez, et al.. (2011). Haploinsufficiency in the Prometastasis Kiss1 Receptor Gpr54 Delays Breast Tumor Initiation, Progression, and Lung Metastasis. Cancer Research. 71(20). 6535–6546. 41 indexed citations
20.
Mark, Tomer M., Melissa Rodríguez, Manan Shah, et al.. (2011). ClaPD (Clarithromycin/[Biaxin®], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma. Blood. 118(21). 635–635. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nermin Kahraman Breakdown of academic impact, for papers by Chun‐Wen Su Breakdown of academic impact, for papers by Hong Xin Breakdown of academic impact, for papers by Ming Ni Breakdown of academic impact, for papers by Hyereen Kang Breakdown of academic impact, for papers by Manman Deng Breakdown of academic impact, for papers by Peifen Cai Breakdown of academic impact, for papers by Shangke Huang Breakdown of academic impact, for papers by Zhimin Fan Breakdown of academic impact, for papers by Sasikumar J. Soumya
Rankless by CCL
2026